The objective of this contract is to use immunogens (ENVS) combined with effective multivalent antigenic display on nanoparticles (NPS) for delivery to promote strong and long-lived neutralizing…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93019C00014
- Awardee
-
Antagen Biosciences Inc. UEI HXD6EFH2ND57
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,914
Award facts
- Opportunity
-
- SBIRPHS20191 Solicitation number
- Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb Award Notice · Posted Jun 29, 2018
- Contract value 100% obligated
- $599,914.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Roxbury, MA 02118, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $599,914 |
About this award
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will focus on using HIV envelope immunogens combined with Antagen's nanoparticle technology to promote somatic hypermutation and the development of HIV-neutralizing antibodies. This contract is set aside for total small business participation.
Description
The objective of this contract is to use immunogens (ENVS) combined with effective multivalent antigenic display on nanoparticles (NPS) for delivery to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies.
Quick answers
Who was awarded contract 75N93019C00014?
75N93019C00014 was awarded to Antagen Biosciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 17, 2019.
How much is contract 75N93019C00014 worth?
The government has obligated $599,914 on 75N93019C00014.
Was contract 75N93019C00014 competed?
The extent of competition for 75N93019C00014 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award